Could a saffron-derived compound boost radiation for sarcoma?

NCT ID NCT06476704

Not yet recruiting Disease control Sponsor: Centre Paul Strauss Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding a drug called liposomal transcrocetin (L-TC) to short-course radiation before surgery can kill more cancer cells in people with soft-tissue sarcoma. About 42 adults with localized or locally advanced sarcoma will be randomly assigned to receive radiation alone or radiation plus L-TC. The main goal is to see if the combination leads to a higher rate of near-complete tumor destruction.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liposomal transcrocetin (L-TC)
What this could lead to: If it works, this could improve the chance of eliminating most cancer cells before surgery, potentially reducing recurrence risk.
What could go wrong: This is a small early-phase trial (42 people) testing a new combination. The drug may not improve outcomes and could cause side effects like infusion reactions or toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED OR LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF THE EXTREMITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypoxia sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA

Contacts and locations

Locations

CGFL

Dijon, France
ICANS

Strasbourg, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.